Phibro Animal Health (NASDAQ:PAHC) Trading Down 6.1% – What’s Next?

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) dropped 6.1% on Monday . The company traded as low as $37.62 and last traded at $37.55. Approximately 120,852 shares were traded during trading, a decline of 59% from the average daily volume of 293,232 shares. The stock had previously closed at $40.00.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. Citigroup assumed coverage on Phibro Animal Health in a report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price objective on the stock. Weiss Ratings downgraded Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and a consensus target price of $42.40.

Phibro Animal Health Stock Down 9.2%

The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 15.59, a P/E/G ratio of 0.61 and a beta of 0.61. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. The firm has a fifty day moving average price of $53.90 and a 200 day moving average price of $46.51.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Sell-side analysts anticipate that Phibro Animal Health Corporation will post 3.06 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, June 3rd. Phibro Animal Health’s payout ratio is presently 20.60%.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 58,014 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $51.81, for a total value of $3,005,705.34. Following the transaction, the chief executive officer directly owned 64,944 shares of the company’s stock, valued at $3,364,748.64. The trade was a 47.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 182,326 shares of company stock valued at $9,584,712. 50.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PAHC. 1620 Investment Advisors Inc. raised its position in Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares during the last quarter. Farther Finance Advisors LLC raised its position in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the last quarter. KBC Group NV bought a new position in Phibro Animal Health in the 1st quarter worth approximately $29,000. Rothschild Investment LLC raised its position in Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Hughes Financial Services LLC bought a new position in Phibro Animal Health in the 3rd quarter worth approximately $40,000. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.